Dudediligence.

NewAmsterdam Pharma Company N.V.

NAMSNASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$29.1MSep ’24$12.8MDec ’24$3.0MMar ’25$19.1MJun ’25$348,000Sep ’25$32,000Dec ’25$3.0MMar ’26$3.7MJun ’26
Net income, by quarter
−$16.6MSep ’24−$92.2MDec ’24−$39.5MMar ’25−$17.4MJun ’25−$72.0MSep ’25−$74.1MDec ’25−$48.4MMar ’26−$64.1MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenuenone on file$102.7M$14.1M$45.6M$22.5M
Operating income−$35.0M−$3.6M−$183.0M−$176.3M−$225.7M
Net income−$41.8M−$22.6M−$176.9M−$241.6M−$203.0M
Operating cash flow−$29.5M$10.7M−$141.2M−$158.6M−$147.8M
Free cash flow−$29.5M$10.4M−$141.2M−$159.2M−$148.0M
Cashnone on filenone on file$340.4M$771.7M$490.0M
Shares outstanding11.0M81.6M82.5M108.1M114.4M